FinTrust Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $1.69K | Hold |
15
| – | – | ﹤0.01% | 1220 |
|
|
2024
Q2 | $2.02K | Hold |
15
| – | – | ﹤0.01% | 1164 |
|
|
2024
Q1 | $2.02K | Hold |
15
| – | – | ﹤0.01% | 1078 |
|
|
2023
Q4 | $1.93K | Sell |
15
-2,000
| -99% | -$258K | ﹤0.01% | 1055 |
|
|
2023
Q3 | $227K | Buy |
2,015
+515
| +34% | +$57.9K | 0.05% | 244 |
|
|
2023
Q2 | $141K | Sell |
1,500
-1,000
| -40% | -$94.3K | 0.03% | 304 |
|
|
2023
Q1 | $253K | Hold |
2,500
| – | – | 0.06% | 227 |
|
|
2022
Q4 | $299K | Buy |
+2,500
| New | +$299K | 0.07% | 209 |
|
|
2021
Q3 | – | Sell |
-118
| Closed | -$11K | – | 1181 |
|
|
2021
Q2 | $11K | Hold |
118
| – | – | ﹤0.01% | 905 |
|
|
2021
Q1 | $11K | Sell |
118
-35
| -23% | -$3.26K | ﹤0.01% | 866 |
|
|
2020
Q4 | $15K | Sell |
153
-41
| -21% | -$4.02K | ﹤0.01% | 730 |
|
|
2020
Q3 | $19 | Sell |
194
-239
| -55% | -$23 | ﹤0.01% | 654 |
|
|
2020
Q2 | $53K | Buy |
+433
| New | +$53K | 0.02% | 471 |
|
|
2019
Q2 | – | Sell |
-2
| Closed | – | – | 1175 |
|
|
2019
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 1302 |
|
|
2018
Q4 | $0 | Buy |
+2
| New | – | ﹤0.01% | 1282 |
|